Therapeutic goals in patients with ACM are to lower the serum insulin-like growth factor-1 (IGF-1) concentrations within the normal range for the patient’s age and gender with or without suppressing GH (growth hormone) nadir to <1.0 ng/L following an oral load of 75 g glucose (oral glucose tolerance test: OGTT), control tumor size to reduce mass effects, improve systemic comorbidities and symptoms, and reverse metabolic alterations [2]. This evidence concerns the gene IGF1 and neoplasm.